Neurology Central

Pfizer cuts Alzheimer’s and Parkinson’s research: industry news round-up

From clinical trial results to major policy change announcements, here we present an overview of the latest industry news from the biggest players in neuroscience and neurology.
Our pick of the biggest headlines this week:
  • Pfizer to end research into novel drugs for Alzheimer’s and Parkinson’s diseases
  • Shire to begin operating as two units, focusing on neuroscience and rare disease
  • Phase III clinical trial results for idalopirdine in the treatment of Alzheimer’s disease
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.